1	Cardiac Abnormalities in Hispanic Women with Prior
2	De Novo Hypertensive Disorders of Pregnancy
3	
4	Odayme Quesada, MD, ^{a,b} Shathiyah Kulandavelu, PhD, ^c Catherine J. Vladutiu, PhD, MPH, ^d
5	Emily DeFranco, DO, MS, ^e Margo B. Minissian, PhD ^f Nour Makarem, PhD, ^g Natalie A. Bello,
6	MD, MPH, ^c Melissa S. Wong, MD, ^h Maria Pabón, MD, ⁱ Alvin A. Chandra, MD, ^j Larissa Avilés-
7	Santa, MD, MPH, ^k Carlos J. Rodríguez, MD, ^I C. Noel Bairey Merz, MD, ^{c,m} Tamar Sofer, PhD, ⁿ
8	Barry E Hurwitz, PhD,° Gregory A. Talavera, MD, MPH, ^p Brian L. Claggett, PhDi Scott D.
9	Solomon, MD, ⁱ Susan Cheng, MD, MPH ^c
10	
11	
12	^a Women's Heart Center, The Christ Hospital Heart and Vascular Institute, Cincinnati, OH; $^{ m b}$ The
13	Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, OH;
14	^c Department of Pediatrics, Miller School of Medicine, Miami, FL; ^d Department of Obstetrics and
15	Gynecology, University of North Carolina, Chapel Hill, NC; ^e Division of Maternal Fetal Medicine,
16	Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, OH; ^f Brawerman
17	Nursing Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ^g Mialman School of Public
18	Health, Columbia University Irving Center, NY, NY; ^h Division of Maternal Fetal Medicine,
19	Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA;
20	ⁱ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School,
21	Boston, MA; ^j University of Texas Southwestern Medical Center, Dallas, TX; ^k National Institute
22	on Minority Health and Health Disparities, Bethesda, MD; ^I Albert Einstein College of Medicine,
23	Bronx, NY; "Barbra Streisand Women's Heart Center; Department of Medicine, Brigham and
24	Women's Hospital, Harvard Medical School, Boston, MA; ^o Department of Psychology, University
25	of Miami, Miami, FL. ^p South Bay Latino Research Center, Department of Psychology, San
26	Diego State University, San Diego, CA.

27

28 Short Title: Cardiac Abnormalities in Women with HDP

29

30 Address for Correspondence:

- 31 Odayme Quesada, MD, Women's Heart Center, The Christ Hospital Heart, Vascular, and Lung
- 32 Institute, Cincinnati, OH, phone 513-585-1777, email odayme.quesada@thechristhospital.com,
- 33 Twitter: @OdaymeMD; and Susan Cheng, MD, MPH, Department of Cardiology, Smidt Heart
- 34 Institute, Cedars Sinai Medical Center
- 35

36 Word count: 6,979

- 37
- 38
- 39

40 ABSTRACT

41	Background. Hypertensive disorders of pregnancy (HDP) are associated with longer-term
42	maternal risks for cardiovascular disease for reasons that remain incompletely understood.
43	Methods. The Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a multi-center
44	community-based cohort of Hispanic/Latino adults recruited 2008 to 2011 was used to evaluate
45	the associations of history of de novo HDP (gestational hypertension, preeclampsia, eclampsia)
46	with echocardiographic measures of left ventricular (LV) structure and function in
47	Hispanic/Latina women with ≥1 prior pregnancy and the proportion of association mediated by
48	current hypertension.
49	Results. The study cohort included 5,168 Hispanic/Latina women. Prior de novo HDP was
50	reported by 724 (14%) of the women studied with an average age of 58.7 \pm 9.7 years at time of
51	echocardiogram and was associated with lower ejection fraction -0.66 (-1.21, -0.11), greater
52	relative wall thickness (RWT) 0.09 (0, 0.18), and 1.39 (1.02, 1.89) greater odds of abnormal LV
53	geometry after adjusting for blood pressure and other risk factors. The proportion of association
54	mediated by current hypertension between HDP and LV ejection fraction was 0.09 (95% CI
55	0.03, 0.45), any abnormal LV geometry was 0.14 (0.12, 0.48), LV RWT 0.28 (0.16, 0.51),
56	concentric LVH was 0.31 (0.19, 0.86), and abnormal LV diastolic dysfunction was 0.58 (0.26,
57	1.79).
58	Conclusions. In a large cohort of Hispanic/Latina women those with de novo HDP had
59	detectable and measurable subclinical alterations in cardiac structure and both systolic and
60	diastolic dysfunction that were only partially mediated by current hypertension.
61	

62

63 KEY WORDS

- 64 Hypertensive disorders of pregnancy, women cardiovascular risk, left ventricular geometry,
- 65 diastolic dysfunction, systolic dysfunction

67 **ABBREVIATIONS**

- 68 BP: blood pressure
- 69 CVD: Cardiovascular disease
- 70 HCHS/SOL: Hispanic Community Health Study/Study of Latinos
- 71 HDP: Hypertensive disorders of pregnancy
- 72 LV: Left ventricle
- 73 LVH: Left ventricular hypertrophy
- 74 RWT: Relative wall thickness
- 75 TTE: Transthoracic echocardiography

77 INTRODUCTION

78 The rates of hypertensive disorders of pregnancy (HDP), including preeclampsia and 79 gestational hypertension, more than doubled from 2007 to 2019 in the United States (U.S.) with 80 highest rates in Non-Hispanic Black and Hispanic/Latina women.^{1,2} Growing evidence 81 demonstrates that history of HDP is associated with higher maternal risk for long-term 82 cardiovascular disease (CVD) and CVD-related death; resulting in the addition of HPDs as risk-83 modifiers in the 2019 American College of Cardiology/ American Heart Association (ACC/AHA) primary prevention guidelines.³⁻⁸ 84 85 86 Prior investigations have found evidence of structural cardiac abnormalities during the 87 antepartum and immediate postpartum period, attributable in part to the short-term 88 hemodynamic effects of pregnancy due to the stress of excess afterload.⁹⁻¹² These cardiac 89 structural changes, including increased left ventricular (LV) wall thickness, LV mass index, 90 diastolic dysfunction and abnormalities in right ventricular (RV) strain, have been shown to 91 persist postpartum.^{11,13,14} However, the role of chronic hypertension on these changes remains 92 debatable. 93 94 Up to 20% of women with pregnancies complicated by HDP remain hypertensive after 6 months 95 postpartum and have a 4-fold lifetime risk of chronic hypertension.¹⁵⁻¹⁷ Some studies show that adverse remodeling is driven by chronic hypertension regardless of HDP-history,^{11,13} whereas 96 97 others demonstrate adverse remodeling associated with HDP is independent of development of 98 chronic hypertension and a cumulative effect in those with both history of HDP and subsequent 99 chronic hypertension.¹⁴ However, very little is known about the effects of HDP on cardiac 100 abnormalities and the role of chronic hypertension in Hispanic/Latina women, one of the 101 fastest-growing ethnic minority group in the U.S. with a diverse and broadly representative 102 genetic architecture.¹⁸

1	02
1	03

104	The degree to which any important cardiac abnormalities occur well beyond the early
105	postpartum period prior to the development of CVD decades later- notwithstanding the effects
106	of postpartum or age-related chronic hypertension – has remained unclear. We hypothesize that
107	history of de novo HDP is associated with pathologic alterations in cardiac structure and
108	function that are only partially mediated by current hypertension. We aimed to examine this
109	hypothesis in a diverse cohort of Hispanic/Latina women in the U.S.
110 111 112 113	METHODS
114	Study Sample
115	We studied participants of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL),

116 a multi-center community-based cohort of all Hispanic/Latino adults representing diverse

117 backgrounds (Central American, Cuban, Dominican, Mexican, Puerto Rican, and South

American).¹⁸ The HCHS/SOL sampling methods and design have been detailed previously.^{19,20}

119 In brief, self-identified Hispanic/Latino men and women were recruited between March 2008 to

120 June 2011 from 4 communities in the United States (Bronx, NY; Chicago, IL; Miami, FL; and

121 San Diego, CA) using a multi-stage area probability sample design. At each stage of sampling,

122 oversampling occurred, and sampling weights were generated to reflect the probabilities of

selection. The institutional review board at each study site approved all protocols, and all study

124 participants provided written informed consent. Data from the HCHS/SOL cohort is publicly

125 available to researchers upon application to NHLBI BIOLINCC.

126

127 Of the 16,415 HCHS/SOL participants who enrolled in this study, we included women age \geq 45

128 years who completed visit 2 and transthoracic echocardiography (TTE) and reported at least 1

129 prior pregnancy at baseline visit (2008-2011) or visit 2 (2014-2017). We excluded men

- 130 (n=4,281), participants that did not complete visit 2 (n=4,792), did not complete echocardiogram
- 131 (n=1,663), participants that were never pregnant or missing data on pregnancy history (n=405),

and participants with missing data on HDP history (n=109). The final sample for this analysis

- 133 included 5,168 women (724 with HDP and 4444 without HDP) (Figure 1).
- 134

135 Clinical and Echocardiographic Data Collection

136 At each study visit, all study participants underwent a standardized assessment of demographic

137 and clinical characteristics including questionnaires regarding medical and pregnancy history

138 along with standardized measurements of blood pressure (BP), as previously described.²⁰⁻²² All

139 participants included had self-reported data on the history of gestational hypertension,

140 preeclampsia and eclampsia for all their pregnancies collected through questionnaires at visit 1

and 2. We defined composite HDP status as any history of de novo gestational hypertension,

142 preeclampsia, or eclampsia.

143

144 At visit 2, participants age \geq 45 years underwent comprehensive 2D TTE performed according to a previously detailed standardized protocol.²³ In brief, TTE examination was performed with the 145 146 participant in the partial left decubitus position with image acquisition techniques and 147 measurements of cardiac structure and function performed according to American Society of 148 Echocardiography guidelines.^{24,25} All image acquisition was performed by centrally trained and 149 certified research sonographers and all imaging measurements were conducted by imaging 150 technical specialists at the core HCHS/SOL Echocardiography Reading Center at Brigham and Women's Hospital.²³ 151

152

As previously described, we defined concentric remodeling as LV mass index \leq 95 gm/m² and RWT >0.42, concentric LVH as LV mass index >95 gm/m² and RWT >0.42, and eccentric LVH as LV mass index >95 gm/m² and RWT \leq 0.42.²⁴ Any abnormal LV geometry was defined as

presence of concentric remodeling, concentric LVH or eccentric LVH. Diastolic function was
graded according to an algorithm that integrates American Society of Echocardiography (ASE)
guidelines²⁶ with Redfield criteria²⁷ as previously described.^{21,28} In the analysis, LV diastolic
dysfunction was dichotomized and grade I-IV diastolic dysfunction was compared to normal
diastolic function.

161

162 Statistical Analyses

163 We compared demographic, clinical, and echocardiographic traits in women with and without 164 prior HDP using the Student's t-test for continuous variables and Chi-square test for categorical 165 variables. Holm-Bonferroni method was used to adjust for multiple comparisons. We then used 166 multivariable-adjusted regression models to examine the association of prior HDP status with 167 established measures of LV structure and function: LV ejection fraction, LV stroke volume, LV 168 mass index, LV end-diastolic diameter, LV mass/end-diastolic volume ratio, LV relative wall 169 thickness (RWT), peak tricuspid regurgitation velocity, lateral E/e' ratio, abnormal LV geometry 170 and LV diastolic function. We constructed linear and logistic regression models for continuous 171 and categorical variables, respectively. For all echocardiographic traits, model 1 adjusted for 172 age, study field center, and Hispanic/Latino background. Model 2 adjusted for the covariates in 173 model 1, in addition to SBP and treatment with antihypertensive therapy at the time of TTE (Visit 174 2). Model 3 adjusted for the covariates in model 2, in addition to body mass index, diabetes, 175 smoking, total number of prior pregnancies, total cholesterol/HDL ratio, and urine albumin-to-176 creatinine ratio all assessed at the time of TTE. Covariates were selected based on prior studies demonstrating association with HDP and/or LV measures of structure/function.^{11,13,14} No 177 178 adjustments were made for multiple testing. Stratified analyses were performed by type of HDP 179 for gestational hypertension and preeclampsia, however the sample size was too small to 180 perform adjusted models for eclampsia. Reported values were survey-weighted, to account for

the complex study design and the non-responses for visit 2.¹⁹ Weights were trimmed and 181 calibrated to the 2010 Census characteristics by age, sex, and Hispanic/Latino background. 182 183 In secondary analyses, we examined the extent to which current hypertension mediated the 184 associations of HDP with echocardiography traits. Models are adjusted for age, field center, 185 Hispanic/Latin background, and current hypertension stage 2 (defined as BP >140/90 mmHg or 186 antihypertensive therapy). These analyses test the extent to which current hypertension mediate 187 the associations of HDP with the given echocardiographic trait, whereby a mediation effect of 0 188 would indicate that current hypertension does not mediate the association and a mediation 189 effect of 1 would indicate that current hypertension mediates all of the association (range of 190 possible effect is from 0 to 1). We also assessed for potential interaction of current hypertension 191 on HDP associations with each of the echocardiographic traits. 192 193 We considered statistical significance as a two-tailed P value and Holm-Bonferroni adjusted P 194 value of less than 0.05. All statistical analysis were conducted using R (v4.0.4). 195 196 RESULTS 197 198 Of the total study sample including 5,168 women with prior pregnancy, 724 (14%) reported a 199 history of de novo HDP including 439 (61%) gestational hypertension, 219 (30%) preeclampsia, 200 and 66 (9%) eclampsia. The mean age at the time of examination and TTE was 58.7±9.7 years. 201 The demographic and clinical characteristics of the study sample at visit 2 are shown in **Table 1**. 202 Women with a history of HDP, compared to those without HDP were younger, had a higher level 203 of education, greater body mass index, and more frequent dyslipidemia. After the Holm-204 Bonferroni adjustment, dyslipidemia and HDL-cholesterol levels were no longer statistically 205 different between the groups. With respect to echocardiographic LV characteristics (**Table 2**), 206 women with prior HDP had lower LV ejection fraction, higher LV stroke volume, greater LV

207 mass index, greater LV RWT, and higher peak tricuspid regurgitation velocity (PTRV).
208 Accordingly, HDP was also associated with greater concentric LVH, presence of any abnormal
209 LV geometry, and presence of abnormal diastolic function. After the Holm-Bonferroni
210 adjustment, LV mass index and PTRV were not significantly different between the groups.
211

212 In multivariable-adjusted analyses of the continuous LV structure and function measures, prior 213 HDP was associated with lower LV ejection fraction in all models including adjustment for 214 systolic BP, antihypertensive therapy and traditional risk factors (P≤0.02) (**Table 3**). Prior HDP 215 was also associated with increased LV RWT in all models ($P \leq 0.039$). Accordingly, among the 216 categorical LV measures, prior HDP was associated with presence of concentric LVH in model 217 1 adjusted for age and demographic factors (P=0.001), but the association was attenuated in 218 analyses adjusting for systolic BP and antihypertensive therapy (P=0.07). Notably, prior HDP 219 was significantly associated with presence of any abnormal LV geometry in all models 220 (P<0.038). In addition, prior HDP was associated with presence of abnormal LV diastolic 221 function in models adjusting for age and demographic factors (P=0.006); this association was 222 attenuated in analyses adjusting for systolic BP and antihypertensive therapy (P=0.43). All other 223 measures of LV structure and function were nonsignificant.

224

225 In secondary analyses, we examined the extent to which current hypertension mediated the 226 associations of HDP with echocardiography traits. We found that the proportion of association 227 between HDP and LV ejection fraction that was mediated by current hypertension was modest 228 at 0.09 (95% CI 0.03, 0.45), with similar results seen for any abnormal LV geometry (0.14 [0.12, 229 0.48]). The proportions of association between HDP and other traits such as LV RWT (0.28 230 [0.16, 0.51]), concentric LVH (0.31 [0.19, 0.86]), and abnormal LV diastolic dysfunction (0.58 231 [0.26, 1.79]) that were mediated by postpartum hypertension were higher, as expected given 232 results of multivariable-adjusted models described above (Table 4). We also assessed for

233 potential interaction of current hypertension on HDP associations with each of the

echocardiographic traits and found no significant interactions (P>0.30 for all). We observed no

235 material difference in any results of analyzing data using survey-weighted versus unweighted

236 values.

237

238 In stratified analysis by type of HDP, there was a trend towards lowest ejection fraction and LV

stroke volume and highest LV RWT in women with eclampsia history (**Supplemental Table 1**).

240 The presence of concentric LVH was highest in women with history of gestational hypertension

and presence of abnormal LV diastolic function was highest in those with history of

242 preeclampsia and gestational hypertension. In multivariable-adjusted analyses, gestational

243 hypertension was associated with LV RWT and 1.79-fold higher risk of abnormal LV geometry

across all models, whereas there was no association between preeclampsia and any of the

245 measures of LV structure and function (**Supplemental Table 2**).

246

247 **DISCUSSION**

248

In our study of over 5,100 Hispanic/Latina women with prior pregnancy, 14% reported de novo
HDP. Women with history of de novo HDP were significantly more likely to have measurable
abnormalities in cardiac structure and function, including lower LV systolic function and higher
rates of abnormal LV geometry than women without history of HDP. These cardiac alterations
were in part mediated by the effects of current hypertension (Central Illustration).

254

The rate of de novo HDP in this study is consistent with the U.S. National Inpatient Sample between 2017 and 2019 which reported 12.5% (95% CI 12.2-12.8).²⁹ To date, a scant number of studies have examined cardiac phenotypes up to a decade or longer following delivery prior to development of clinical CVD; these few studies, each involving sample sizes of less than 200

women with history of HDP, have found evidence of LVH or diastolic dysfunction.^{30,31} In studies 259 260 accounting for chronic hypertension, findings have also been mixed on whether or not the 261 changes in LV structure and function associated with HDP history are present after adjusting for 262 chronic hypertension – an obvious potentially confounding contributor to subsequent cardiac risk.^{11,13,14} We extend previous work and analyze one of the largest samples of de novo HDP in 263 264 724 women and compared their cardiac phenotypes with 4444 similarly aged clinical controls 265 (i.e. women with prior pregnancy but no HDP). Importantly, we found that prior HDP was 266 associated with higher LV RWT and abnormal LV geometry – even after adjusting for current hypertension and CV risk factors – consistent with a recent study by Countouris et al.¹⁴ in a 267 268 cohort of NHW and Black women. Our study extends these findings to Hispanic/Latina women 269 who are underrepresented in research studies.

270

271 In this study history of pregnancy complicated by de novo HDP was associated with higher risk 272 of abnormal LV geometry (defined as concentric LV remodeling, concentric LVH, or eccentric 273 LVH as determined by LVMI and RWT) even after adjusting for important confounders. These 274 findings are of clinical significance because abnormal LV geometry, particularly LVH, is an 275 independent predictor of adverse CVD events including heart failure, ischemic heart disease, 276 and sudden cardiac death.³²⁻³⁴ We also found an association between de novo HDP and 277 abnormal LV diastolic function, which is linked with higher incidence of CVD events in healthy 278 cohorts and is a strong predictor of progression to heart failure with preserved ejection fraction 279 (HFpEF).^{35,36} Further, individual measures of LV geometry (LVMI, LV RWT) that we found to be 280 associated with history of de novo HDP have also been shown to be associated with CVD 281 events. For instance, in the Framingham Heart Study of Offspring cohort among adults free of 282 CVD, each 10 g/m2 increment in LVMI was associated with 33% increased risk of CVD and each 0.1 unit in LV RWT was associated with 59% increased risk of CVD.³⁷ 283

284

285 Further, this is the first known study to identify evidence of HDP associated with decrements in LV systolic function. The finding of slightly lower LV ejection fraction despite greater concentric 286 287 remodeling and a trend towards greater stroke volume suggests a type of contractile inefficiency 288 that is not typically seen in the setting of current hypertension alone, suggesting a 289 pathophysiology distinct form of hypertensive heart disease. These findings and the diastolic 290 dysfunction exhibited by these mothers all suggest a pre- HFpEF remodeling phenotype, 291 supported by the excess risk of HFpEF in women with preeclampsia, that warrants further 292 investigation.38,39 293

294 Hypertension results in chronic central pressure overload and myocardial ischemia that leads to 295 the development of LVH and heart failure. Therefore, we evaluated the extent to which current 296 hypertension mediated the association between history of de novo HDP and measures of LV 297 structure and function. Hypertension is associated with significantly higher rates of concentric 298 LVH and is a strong independent predictor of LV diastolic dysfunction, but the association with 299 eccentric LVH and LV systolic dysfunction is less robust.^{40,41} This helps explain why 300 hypertension was a moderate mediator in the association between HDP and concentric LVH 301 and LV diastolic dysfunction but a weaker mediator of LV ejection fraction (a measure of LV 302 systolic function). Our results are consistent with large epidemiologic data indicating that the 303 association of HDP with later-life CVD is only partially mediated by current hypertension.⁵ These 304 findings provide insights into HDP as a potential novel mechanism to explain the 305 disproportionally higher risk of heart failure in women with a history of HDP.^{42,43} 306 307 The mechanisms by which HDP may lead to abnormalities in cardiac structure and function 308 beyond the effects of current hypertension remain to be elucidated.⁴⁴ Diabetes was found to be

309 higher in women with history of de novo HDP and although we included diabetes in our adjusted

310 models it may have contributed to some of our findings. In fact, glucose intolerance, insulin

311 resistance, and diabetes have been shown to be associated with increased LV mass and wall thickness and reduced end-diastolic volume, stroke volume, and election fraction.⁴⁵⁻⁴⁷ Further. 312 313 endothelial dysfunction is a hallmark of the pathophysiology underlying preeclampsia and some studies suggest this can persist after delivery.^{48,49} Activation of pathways involving the 314 315 antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt-1) in preeclampsia, which can remain at 316 least modestly elevated postpartum, can contribute to endothelial dysfunction and deranged 317 lipid metabolism.⁵⁰⁻⁵² Dysregulations of the renin-angiotensin system may also contribute to 318 persistent postpartum cardiac abnormalities. Additionally, shared upstream factors such as CV 319 risk factors and/or genetics may predispose women to both HDPs and later in life pathological 320 LV remodeling and function. Further investigations are needed to identify the potential 321 mechanisms contributing to cardiac abnormalities and how these may be different by race and 322 ethnicity.

323

324 Study Limitations

325 Several limitations of our study merit consideration. The cross-sectional design of our study 326 precludes inference of causality, although timing of reported prior HDP consistently preceded 327 timing of assessed cardiac traits. Prior HDP status was based on self-report, which is subject to 328 recall bias and limits precision with respect to subtypes of HDP; nonetheless, self-report has 329 been evaluated as valid and thus applied in the vast majority of cohort studies on HDP.^{53,54} Data 330 on severity of preeclampsia, number of pregnancies complicated by HDP, time period between 331 HDP pregnancy and echocardiography, and length of postpartum hypertension is not available. 332 Additionally, multiple echocardiographic measures were analyzed, which can lead to heightened 333 Type 1 error rate. Despite these limitations, our study offered several strengths including 334 analyses from the largest study to date investigating the relations of prior HDP with cardiac traits 335 in Hispanic/Latina women who represent a demographically important yet historically 336 understudied population. In addition, all cardiac traits were assessed from echocardiographic

protocols that involved standardized image acquisition and centralized measures performed at a
 core center with high inter- and intra-reader reproducibility and BP obtained in a standardized
 method.

340

341 Conclusions

342 In summary, we found in a large cohort of previously pregnant Hispanic/Latina women that 343 those with history of de novo HDP had detectable and measurable pathological alterations in 344 cardiac structure and systolic and diastolic dysfunction. Our findings suggest that women with 345 prior HDP have pathophysiologic cardiac sequelae decades later, that likely play a role in 346 modulating long-term CV risk. Notwithstanding the need for further investigations into the 347 mechanisms driving HDP pathophysiology, our findings highlight the potential importance of 348 targeted surveillance and interventions aimed at preventing later-life CVD events in these at-risk 349 understudied women.

350

351 **Perspectives**

352 Hispanic/Latina women are disproportionally affected by HDP, yet very little is known on how 353 HDP affects cardiac structure and function in this growing population in the U.S. In this study of 354 a diverse cohort of Hispanic/Latina women, those with history of de novo HDP had higher rates 355 of abnormal LV geometry, and alterations in LV geometry (LVMI, RWT) and function (LVEF, 356 diastolic dysfunction), known predictors of CV events and mortality. Notably, these findings 357 appear to be in part mediated by current hypertension – underscoring the importance of 358 screening for and managing hypertension in this cohort. Hypertension alone did not account for 359 all the associations between history of de novo HDP and morphologic and functional cardiac 360 alterations. With the higher rates of heart failure, particularly HFpEF, in women and the 361 alterations in cardiac structure and function identified in this study we hypothesize HDP may be 362 a sex-specific risk factor that warrants further investigation.

363 Acknowledgements:

The authors thank the participants and staff of HCHS/SOL for their important contributions to this research. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

368

369 Sources of Funding:

- 370 The HCHS/SOL study is a collaborative study supported by National Heart, Lung, and Blood
- 371 Institute (NHLBI) contracts N01-HC65233, N01-HC65234, N01-HC65235, N01-HC65236, and
- N01-HC65237. The following institutes, centers, or offices contribute to the HCHS/SOL through
- 373 a transfer of funds to the NHLBI: National Center on Minority Health and Health Disparities, the
- 374 National Institute on Deafness and Other Communications Disorders, the National Institute of
- 375 Dental and Craniofacial Research, the National Institute of Diabetes and Digestive and Kidney
- 376 Diseases, the National Institute of Neurological Disorders and Stroke, and the Office of Dietary
- 377 Supplements. The authors report the following additional sources of funding: NIH K23-
- 378 HL136853, NIH K23-HL151867, Erika J. Glazer Women's Heart Research Initiative, and the
- 379 Barbra Streisand Women's Cardiovascular Research and Education Program.

- 381 Disclosures
- 382 The authors report no relevant disclosures.
- 383
- 384

385 **REFERENCES**

- Freaney PM, Harrington K, Molsberry R, Perak AM, Wang MC, Grobman W, Greenland
 P, Allen NB, Capewell S, O'Flaherty M, et al. Temporal Trends in Adverse Pregnancy
 Outcomes in Birthing Individuals Aged 15 to 44 Years in the United States, 2007 to
 2019. J Am Heart Assoc. 2022;11:e025050. doi: 10.1161/JAHA.121.025050
- Shah NS, Harrington KA, Huang X, Cameron NA, Yee LM, Khan SS. Trends in De Novo Hypertensive Disorders of Pregnancy Among Asian and Hispanic Population Subgroups in the United States, 2011 to 2019. *JAMA Cardiol*. 2022;7:742-746. doi: 10.1001/jamacardio.2022.1378
- Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of
 cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*.
 2007;335:974. doi: 10.1136/bmj.39335.385301.BE
- Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O,
 Weissgerber TL, Milic N, Weaver A, Mielke MM. Incidence and Long-Term Outcomes
 of Hypertensive Disorders of Pregnancy. *J Am Coll Cardiol*. 2020;75:2323-2334. doi:
 10.1016/j.jacc.2020.03.028
- 401 5. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, Peloso GM,
 402 Natarajan P. Long-Term Cardiovascular Risk in Women With Hypertension During
 403 Pregnancy. J Am Coll Cardiol. 2019;74:2743-2754. doi: 10.1016/j.jacc.2019.09.052
- 404 6. Torosyan N, Aziz D, Quesada O. Long-term sequelae of adverse pregnancy outcomes.
 405 *Maturitas*. 2022;165:1-7. doi: 10.1016/j.maturitas.2022.06.012
- Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer
 AA, Kadam U, Chew-Graham CA, et al. Preeclampsia and Future Cardiovascular Health:
 A Systematic Review and Meta-Analysis. *Circ Cardiovasc Qual Outcomes*. 2017;10. doi:
 10.1161/CIRCOUTCOMES.116.003497
- 410 8. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ,
- 411 Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA
 412 Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the
 412 Clinic Control of Cardiovascular Disease: A Control of Cardiovascular Disease: A Control of Cardiovascular Disease: A Report of the
- 413American College of Cardiology/American Heart Association Task Force on Clinical414Practice Guidelines. *Circulation*. 2019;140:e596-e646. doi:
- 415 10.1161/CIR.000000000000678
- 416 9. Castleman JS, Ganapathy R, Taki F, Lip GY, Steeds RP, Kotecha D. Echocardiographic
 417 Structure and Function in Hypertensive Disorders of Pregnancy: A Systematic Review.
 418 *Circ Cardiovasc Imaging*. 2016;9. doi: 10.1161/CIRCIMAGING.116.004888
- 419 10. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal
 420 cardiac dysfunction and remodeling in women with preeclampsia at term. *Hypertension*.
 421 2011;57:85-93. doi: 10.1161/HYPERTENSIONAHA.110.162321
- Scantlebury DC, Kane GC, Wiste HJ, Bailey KR, Turner ST, Arnett DK, Devereux RB,
 Mosley TH, Jr., Hunt SC, Weder AB, et al. Left ventricular hypertrophy after
 hypertensive pregnancy disorders. *Heart*. 2015;101:1584-1590. doi: 10.1136/heartjnl2015-308098
- 426 12. Vaught AJ, Kovell LC, Szymanski LM, Mayer SA, Seifert SM, Vaidya D, Murphy JD,
- 427 Argani C, O'Kelly A, York S, et al. Acute Cardiac Effects of Severe Pre-Eclampsia. J Am
 428 Coll Cardiol. 2018;72:1-11. doi: 10.1016/j.jacc.2018.04.048
- 429 13. Levine LD, Ky B, Chirinos JA, Koshinksi J, Arany Z, Riis V, Elovitz MA, Koelper N,
 430 Lewey J. Prospective Evaluation of Cardiovascular Risk 10 Years After a Hypertensive

421		Disorder of Brognon and I Am Coll Condict 2022-70-2401 2411 doi:
431		Disorder of Pregnancy. $JAM Coll Caralol. 2022; 79:2401-2411. doi:10.1016/j.jaca.2022.02.292$
432	14	10.1010/J.jacc.2022.03.383
433	14.	Countouris ME, Villanueva FS, Berlacher KL, Cavalcante JL, Parks W I, Catov JM.
434		Association of Hypertensive Disorders of Pregnancy With Left Ventricular Remodeling
435		Later in Life. J Am Coll Cardiol. 2021;77:1057-1068. doi: 10.1016/j.jacc.2020.12.051
436	15.	Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, Thilaganathan B,
437		Boyd HA. Risk of post-pregnancy hypertension in women with a history of hypertensive
438		disorders of pregnancy: nationwide cohort study. BMJ. 2017;358:j3078. doi:
439		10.1136/bmj.j3078
440	16.	Benschop L, Duvekot JJ, Versmissen J, van Broekhoven V, Steegers EAP, Roeters van
441		Lennep JE. Blood Pressure Profile 1 Year After Severe Preeclampsia. Hypertension.
442		2018;71:491-498. doi: 10.1161/HYPERTENSIONAHA.117.10338
443	17.	Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia.
444		Hypertens Pregnancy. 2010;29:294-300. doi: 10.3109/10641950902777747
445	18.	Conomos MP, Laurie CA, Stilp AM, Gogarten SM, McHugh CP, Nelson SC, Sofer T,
446		Fernandez-Rhodes L, Justice AE, Graff M, et al. Genetic Diversity and Association
447		Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community
448		Health Study/Study of Latinos. Am J Hum Genet. 2016;98:165-184. doi:
449		10.1016/j.ajhg.2015.12.001
450	19.	Lavange LM, Kalsbeek WD, Sorlie PD, Aviles-Santa LM, Kaplan RC, Barnhart J, Liu K,
451		Giachello A, Lee DJ, Ryan J, et al. Sample design and cohort selection in the Hispanic
452		Community Health Study/Study of Latinos. Ann Epidemiol. 2010;20:642-649. doi:
453		10.1016/j.annepidem.2010.05.006
454	20.	Sorlie PD, Aviles-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML,
455		Giachello AL, Schneiderman N, Raij L, Talavera G, Allison M, et al. Design and
456		implementation of the Hispanic Community Health Study/Study of Latinos. Ann
457		<i>Epidemiol.</i> 2010:20:629-641. doi: 10.1016/j.annepidem.2010.03.015
458	21.	Aggarwal SR, Herrington DM, Vladutiu CJ, Newman JC, Swett K, Gonzalez F, Kizer JR.
459		Kominiarek MA, Tabb KM, Gallo LC, et al. Higher number of live births is associated
460		with left ventricular diastolic dysfunction and adverse cardiac remodelling among US
461		Hispanic/Latina women: results from the Echocardiographic Study of Latinos. <i>Open</i>
462		Heart 2017:4:e000530 doi: 10.1136/openhrt-2016-000530
463	22	Vladutiu CL Siega-Riz AM Sotres-Alvarez D Stuebe AM Ni A Tabb KM Gallo I C
464		Potter IF Heiss G Parity and Components of the Metabolic Syndrome Among US
465		Hispanic/Latina Women Circulation: Cardiovascular Quality and Outcomes
405 166		2016:0:S62-S60 doi: doi:10.1161/CIRCOUTCOMES.115.002464
400	23	Shah AM Cheng S Skali H Wu I Mangion IR Kitzman D Matsushita K Konety S
-07 168	23.	Butler KR Fox FR at al Rationale and design of a multicenter echocardiographic study
460		to assass the relationship between cardiac structure and function and heart failure risk in a
409		biragial schort of community dwalling alderly persons; the Atherosalerosis Pisk in
470		Communities study. Circ Candioussa Imaging 2014;7:172–181. doi:
4/1 472		Communues study. <i>Circ Caratovasc Imaging</i> . 2014;7:173-181. doi:
4/2	24	10.1101/circimaging.115.000/50
4/3	24.	Lang Kivi, Dadano LP, Nior-Avi V, Ailiaio J, Armstrong A, Ernande L, Flachskampi FA,
4/4		roster E, Goldstein SA, Kuznetsova I, et al. Recommendations for cardiac chamber
475		quantification by echocardiography in adults: an update from the American Society of

476		Echocardiography and the European Association of Cardiovascular Imaging. European
477		heart journal cardiovascular Imaging, 2015;16:233-270. doi: 10.1093/ehici/jev014
478	25.	Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T,
479		Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the
480		Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from
481		the American Society of Echocardiography and the European Association
482		of Cardiovascular Imaging, J Am Soc Echocardiogr. 2016:29:277-314. doi:
483		10.1016/i.echo.2016.01.011
484	26.	Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD,
485		Flachskampf FA. Pellikka PA. Evangelista A. Recommendations for the evaluation of
486		left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr.
487		2009;22:107-133. doi: 10.1016/j.echo.2008.11.023
488	27.	Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahonev DW, Bailev KR, Rodeheffer RJ.
489		Burden of systolic and diastolic ventricular dysfunction in the community: appreciating
490		the scope of the heart failure epidemic. <i>Jama</i> , 2003:289:194-202. doi:
491		10.1001/jama.289.2.194
492	28.	Mehta H, Armstrong A, Swett K, Shah SJ, Allison MA, Hurwitz B, Bangdiwala S,
493		Dadhania R. Kitzman DW. Arguelles W. et al. Burden of Systolic and Diastolic Left
494		Ventricular Dysfunction Among Hispanics in the United States: Insights From the
495		Echocardiographic Study of Latinos, <i>Circ Heart Fail</i> , 2016;9:e002733. doi:
496		10.1161/circheartfailure.115.002733
497	29.	Ford ND, Cox S, Ko JY, Ouvang L, Romero L, Colarusso T, Ferre CD, Kroelinger CD,
498		Haves DK, Barfield WD. Hypertensive Disorders in Pregnancy and Mortality at Delivery
499		Hospitalization - United States, 2017-2019. MMWR Morb Mortal Wkly Rep.
500		2022;71:585-591. doi: 10.15585/mmwr.mm7117a1
501	30.	Boardman H, Lamata P, Lazdam M, Verburg A, Siepmann T, Upton R, Bilderbeck A,
502		Dore R, Smedley C, Kenworthy Y, et al. Variations in Cardiovascular Structure,
503		Function, and Geometry in Midlife Associated With a History of Hypertensive
504		Pregnancy. Hypertension. 2020;75:1542-1550. doi:
505		10.1161/HYPERTENSIONAHA.119.14530
506	31.	Bokslag A, Franssen C, Alma LJ, Kovacevic I, Kesteren FV, Teunissen PW, Kamp O,
507		Ganzevoort W, Hordijk PL, Groot CJM, et al. Early-onset preeclampsia predisposes to
508		preclinical diastolic left ventricular dysfunction in the fifth decade of life: An
509		observational study. PLoS One. 2018;13:e0198908. doi: 10.1371/journal.pone.0198908
510	32.	Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, Folsom AR. The
511		relationship of left ventricular mass and geometry to incident cardiovascular events: the
512		MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;52:2148-
513		2155. doi: 10.1016/j.jacc.2008.09.014
514	33.	Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age-
515		related left ventricular remodeling and associated risk for cardiovascular outcomes: the
516		Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2009;2:191-198. doi:
517		10.1161/CIRCIMAGING.108.819938
518	34.	Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of
519		echocardiographically determined left ventricular mass in the Framingham Heart Study.
520		N Engl J Med. 1990;322:1561-1566. doi: 10.1056/NEJM199005313222203

- 35. Nayor M, Cooper LL, Enserro DM, Xanthakis V, Larson MG, Benjamin EJ, Aragam J,
 Mitchell GF, Vasan RS. Left Ventricular Diastolic Dysfunction in the Community:
 Impact of Diagnostic Criteria on the Burden, Correlates, and Prognosis. *J Am Heart Assoc.* 2018;7. doi: 10.1161/JAHA.117.008291
 Yang CG, Karaga DL, Malaga DW, Padfield MM, Pagar ML, Parastta IC, Jan Janaka
- 525 36. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC, Jr., Jacobsen
 526 SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart
 527 failure. JAMA. 2011;306:856-863. doi: 10.1001/jama.2011.1201
- 528 37. Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ, O'Donnell CJ. Left
 529 Ventricular Structure and Risk of Cardiovascular Events: A Framingham Heart Study
 530 Cardiac Magnetic Resonance Study. J Am Heart Assoc. 2015;4:e002188. doi:
 531 10.1161/JAHA.115.002188
- 38. Williams D, Stout MJ, Rosenbloom JI, Olsen MA, Joynt Maddox KE, Deych E, DavilaRoman VG, Lindley KJ. Preeclampsia Predicts Risk of Hospitalization for Heart Failure
 With Preserved Ejection Fraction. *J Am Coll Cardiol*. 2021;78:2281-2290. doi:
 10.1016/j.jacc.2021.09.1360
- 39. Hansen ÅL, Sondergaard MM, Hlatky MA, Vittinghof E, Nah G, Stefanick ML, Manson
 JE, Farland LV, Wells GL, Mongraw-Chaffin M, et al. Adverse Pregnancy Outcomes and
 Incident Heart Failure in the Women's Health Initiative. *JAMA Netw Open*.
 2021;4:e2138071. doi: 10.1001/jamanetworkopen.2021.38071
- 540 40. Yun M, Li S, Yan Y, Sun D, Guo Y, Fernandez C, Bazzano L, He J, Zhang T, Chen W.
 541 Blood Pressure and Left Ventricular Geometric Changes: A Directionality Analysis.
 542 *Hypertension*. 2021;78:1259-1266. doi: 10.1161/HYPERTENSIONAHA.121.18035
- 543 41. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left
 544 ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and
 545 prognostic value. *Hypertension*. 2005;45:412-418. doi:
 546 10.11(1/01 UVD 0000154922.27141 %)
- 546 10.1161/01.HYP.0000154822.37141.f6
- 547 42. Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H, Melbye M, Boyd
 548 HA. Association Between Hypertensive Disorders of Pregnancy and Later Risk of
 549 Cardiomyopathy. *JAMA*. 2016;315:1026-1033. doi: 10.1001/jama.2016.1869
- 43. Honigberg MC, Riise HKR, Daltveit AK, Tell GS, Sulo G, Igland J, Klungsoyr K, Scott
 551 NS, Wood MJ, Natarajan P, et al. Heart Failure in Women With Hypertensive Disorders
 552 of Pregnancy: Insights From the Cardiovascular Disease in Norway Project.
- 553 *Hypertension*. 2020;76:1506-1513. doi: 10.1161/HYPERTENSIONAHA.120.15654
- 44. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology,
 Challenges, and Perspectives. *Circ Res.* 2019;124:1094-1112. doi:
 10.1161/CIRCRESAHA.118.313276
- 45. Kishi S, Gidding SS, Reis JP, Colangelo LA, Venkatesh BA, Armstrong AC, Isogawa A,
 Lewis CE, Wu C, Jacobs DR, Jr., et al. Association of Insulin Resistance and Glycemic
 Metabolic Abnormalities With LV Structure and Function in Middle Age: The CARDIA
- 560 Study. *JACC Cardiovasc Imaging*. 2017;10:105-114. doi: 10.1016/j.jcmg.2016.02.033
- 46. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, Wilson
 PW, Vasan RS. Impact of glucose intolerance and insulin resistance on cardiac structure
 and function: sex-related differences in the Framingham Heart Study. *Circulation*.
 2003;107:448-454. doi: 10.1161/01.cir.0000045671.62860.98
- 565 47. Lv J, Liu Y, Yan Y, Sun D, Fan L, Guo Y, Fernandez C, Bazzano L, He J, Li S, et al.
 566 Relationship Between Left Ventricular Hypertrophy and Diabetes Is Likely Bidirectional:

567		A Temporality Analysis. J Am Heart Assoc. 2023;12:e028219. doi:
568		10.1161/JAHA.122.028219
569	48.	Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH.
570		Endothelial dysfunction and raised plasma concentrations of asymmetric
571		dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet.
572		2003;361:1511-1517. doi: 10.1016/S0140-6736(03)13177-7
573	49.	Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ, Price K,
574		Karumanchi SA, Valdes G. Endothelial dysfunction: a link among preeclampsia,
575		recurrent pregnancy loss, and future cardiovascular events? Hypertension. 2007;49:90-
576		95. doi: 10.1161/01.HYP.0000251522.18094.d4
577	50.	Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, Rajakumar A, Daftary A,
578		Shakir AS, Seely EW, et al. Preeclampsia and future cardiovascular disease: potential
579		role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab.
580		2004;89:6239-6243. doi: 10.1210/jc.2004-0548
581	51.	Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP,
582		Sellke FW, Stillman IE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1)
583		may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
584		J Clin Invest. 2003;111:649-658. doi: 10.1172/JCI17189
585	52.	Bytautiene E, Bulayeva N, Bhat G, Li L, Rosenblatt KP, Saade GR. Long-term
586		alterations in maternal plasma proteome after sFlt1-induced preeclampsia in mice. Am J
587		Obstet Gynecol. 2013;208:388.e381-388.e310. doi: 10.1016/j.ajog.2013.01.042
588	53.	Stuart JJ, Bairey Merz CN, Berga SL, Miller VM, Ouyang P, Shufelt CL, Steiner M,
589		Wenger NK, Rich-Edwards JW. Maternal recall of hypertensive disorders in pregnancy:
590		a systematic review. J Womens Health (Larchmt). 2013;22:37-47. doi:
591		10.1089/jwh.2012.3740
592	54.	Carter EB, Stuart JJ, Farland LV, Rich-Edwards JW, Zera CA, McElrath TF, Seely EW.
593		Pregnancy Complications as Markers for Subsequent Maternal Cardiovascular Disease:
594		Validation of a Maternal Recall Questionnaire. J Womens Health (Larchmt).
595		2015;24:702-712. doi: 10.1089/jwh.2014.4953
596		

597 Pathophysiological Novelty and Relevance

598 What is new?

- First study to evaluate the cardiac sequelae of de novo hypertensive disorder of
- 600 pregnancy (HDP) in a cohort of 5,168 Hispanic/Latina women.

601 What is relevant?

- Women with de novo HDP had detectable and measurable subclinical alterations in
- 603 cardiac structure and both systolic and diastolic dysfunction, above and beyond the
- 604 effects of current hypertension.

605 **Clinical/Pathophysiologic Implications?**

- Our findings suggest that women with de novo HDP have pathophysiologic cardiac
- 607 sequelae decades later that likely play a role in modulating long-term cardiovascular risk
- in women.

610 Figure Legend

- 611 **Figure 1.** Sampling Strategy and Study Design.
- 612 **Central Illustration.** Proportion of association between hypertensive disorders of pregnancy
- 613 and measures of left ventricular structure and function mediated by current hypertension.
- 614 Figure created using BioRender.

- 616
- 617

 Table 1. Demographics and Clinical Characteristics by De Novo Hypertensive Disorders of Pregnancy History

Characteristics at Visit 2		De Novo Hypertensive Disorders of Pregnancy History			
	Overall	No	Yes	Durahua	Adjusted
	N=5168	N=4444	N=724	P value	P value
Demographics					
Age, years, mean (SD)	58.7 (9.7)	59.2 (9.7)	56.3 (8.8)	<0.001	<0.001
Hispanic/Latino Background, %				0.07	0.68
Dominican	11	11	13		
Central/South American	12	12	12		
Cuban	22	22	23		
Mexican	34	36	28		
Puerto-Rican	18	17	21		
Other or more than one heritage	3	2	4		
Participant's Field Center, %				0.1	0.86
Bronx	29	28	33		
Chicago	13	13	11		
Miami	32	32	34		
San Diego	26	27	23		
Years living in US, years, mean (SD)	29.3 (16.6)	29.3 (16.5)	28.9 (16.7)	0.71	1.0
Annual Family income ≥\$30,000, %	62	62	62	1.0	1.0
Health Insurance Coverage, %	81	81	82	0.49	1.0
Clinical Characteristics					
Blood pressure based on ACC/AHA, %				<0.001	<0.001
Normal	27	30	18		
Elevated BP	9	10	6		
Stage 1 Hypertension	43	41	58		
Stage 2 Hypertension	11	11	10		
Antihypertensive therapy, %	43	41	58	<0.001	<0.001

Diabetes Mellitus, %	31	30	39	<0.001	<0.001
Dyslipidemia, %	30	29	35	0.021	0.27
Metabolic Syndrome, %	53	51	63	<0.001	<0.001
Current smoker, %	13	13	14	0.66	1.0
Number of Pregnancy, mean (SD)	4 (2)	4 (2)	4 (2)	0.6	1.0
HDP Type, %					
Gestational Hypertension	61	-	61		
Preeclampsia	30	-	30		
Eclampsia	9	-	9		
Clinical Measures					
Systolic blood pressure, mmHg, mean (SD)	127 (20)	127 (20)	129 (19)	0.047	0.51
Diastolic blood pressure, mmHg, mean (SD)	73 (11)	72 (10)	76 (12)	<0.001	<0.001
Body Mass Index, kg/m ² , mean (SD)	31 (6)	30 (6)	32 (7)	<0.001	<0.001
Cholesterol, Total, mg/dL, mean (SD)	201 (40)	200 (40)	203 (41)	0.31	1.0
LDL cholesterol, mg/dL, mean (SD)	121 (36)	121 (36)	121 (37)	0.76	1.0
HDL cholesterol, mg/dL, mean (SD)	54 (15)	55 (15)	53 (15)	0.032	0.38
Triglycerides, mg/dL, mean (SD)	130 (80)	127 (72)	144 (116)	0.003	0.049
Urine Albumin/creatinine ratio, mean (SD)	46 (330)	40 (318)	77 (404)	0.12	0.93

Table 2. Differences in Measures of Left Ventricle Structure and Function by De Novo Hypertensive Disorders of Pregnancy

History

		De Novo Hypertensive Disorders of Pregnancy History			
Echocardiographic Measures	Overall	No	Yes	P value	Adjusted P value
Continuous Measures					
LV ejection fraction, %	71.55 (4.50)	71.72 (4.44)	70.68 (4.76)	<0.001	0.005
LV stroke volume, mL	60.35 (11.43)	59.86 (11.15)	62.65 (12.42)	<0.001	0.003
LV mass index, g/m ²	76.09 (16.57)	75.61 (15.90)	78.40 (19.35)	0.015	0.12
LV end-diastolic diameter, cm	4.24 (0.37)	4.23 (0.36)	4.26 (0.41)	0.24	1.0
LVMI/EDV ratio	0.92 (0.24)	0.93 (0.23)	0.90 (0.25)	0.13	0.79
LV relative wall thickness, cm	0.44 (0.07)	0.44 (0.07)	0.46 (0.07)	0.001	0.009
PTRV, cm/s	220.48 (30.04)	219.72 (30.36)	224.90 (27.94)	0.045	0.32
Lateral E/e' ratio	8.8 (3.4)	8.7 (3.4)	8.9 (3.4)	0.38	1.0
Categorical Measures					
Concentric LV remodeling, %	46	45	49	0.26	1.0
Concentric LVH, %	9	8	13	0.005	0.04
Eccentric LVH, %	3	2	5	0.2	1.0
Abnormal LV geometry, %	57	56	66	0.002	0.017
Abnormal LV diastolic function, %	35	35	35	0.98	1.0

LV, left ventricle; LVMI, LV mass index; EDV, end-diastolic volume; PTRG, Peak tricuspid regurgitation velocity; LVH, left ventricular hypertrophy

Table 3. Associations between De Novo Hypertensive Disorders of Pregnancy History and Measures of Left Ventricle

Structure and Function.

Echocardicarenhia Macauraa	Model 1		Model 2		Model 3	
	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value
Continuous Measures						
LV ejection fraction, %	-0.90 (-1.45, -0.04)	0.001	-0.75 (-1.30, -0.21)	0.007	-0.66 (-1.21, -0.11)	0.02
LV stroke volume, mL	1.72 (0.32, 3.12)	0.016	0.94 (-0.41, 2.29)	0.17	0.32 (-0.96, 1.61)	0.62
LV mass index, g/m ²	3.70 (1.46, 5.94)	0.001	1.57 (-0.50, 3.64)	0.14	1.05 (-1.01, 3.10)	0.32
LV end-diastolic diameter, cm	0.01 (-0.49, 0.52)	0.96	-0.12 (-0.62, 0.38)	0.65	-0.29 (-0.75, 0.18)	0.23
LVMI/EDV ratio	0.01 (-0.03, 0.04)	0.72	-0.01 (-0.04, 0.03)	0.72	0 (-0.04, 0.03)	0.92
LV relative wall thickness, cm	0.22 (0.13, 0.31)	<0.001	0.14 (0.05, 0.23)	0.003	0.09 (0.00, 0.18)	0.039
PTRV, cm/s	7.37 (2.50, 12.25)	0.003	4.0 (-0.92, 8.92)	0.11	2.22 (-2.65, 7.09)	0.37
Lateral E/e' ratio	0.58 (0.19, 0.96)	0.004	0.19 (-0.19, 0.58)	0.33	0 (-0.37, 0.38)	0.10
Categorical Measures						
Concentric LV remodeling, %	1.33 (1.01, 1.75)	0.046	1.25 (0.94, 1.67)	0.12	1.16 (0.87, 1.55)	0.31
Concentric LVH, %	1.92 (1.32, 2.79)	0.001	1.45 (0.97, 2.16)	0.07	1.30 (0.85, 1.99)	0.22
Eccentric LVH, %	1.60 (0.80, 3.21)	0.19	1.32 (0.64, 2.75)	0.45	1.38 (0.63, 3.00)	0.42
Abnormal LV geometry, %	1.86 (1.39, 2.49)	<0.001	1.51 (1.12, 2.03)	0.007	1.39 (1.02, 1.89)	0.038
Abnormal LV diastolic function, %	1.52 (1.13, 2.05)	0.006	1.14 (0.83, 1.57)	0.43	1.02 (0.73, 1.42)	0.90

LV, left ventricle; LVMI, LV mass index; EDV, end-diastolic volume; PTRG, Peak tricuspid regurgitation velocity; LVH, left ventricular hypertrophy

Model 1 is adjusted for age, field center, Hispanic background; Model 2 is adjusted for all variables in Model 1, in addition to systolic blood pressure and antihypertensive therapy at Visit 2; Model 3 is adjusted for all variables in Model 2, in addition to diabetes status, smoking, total cholesterol HDL ratio, number of pregnancies, BMI, urine albumin-to-creatinine ratio

Table 4. Causal Mediation Analysis to Assess Mediation Effect of Current Hypertension for Observed Association Between

De Novo Hypertensive Disorders of Pregnancy and Measures of Left Ventricle Structure and Function.

Echocardiographic Measures	Proportion of Association with HDP Mediated by Current Hypertension (95% CI)	P value
LV ejection fraction	0.09 (0.03, 0.45)	0.01
LV relative wall thickness	0.28 (0.16, 0.51)	<0.001
Concentric LVH	0.31 (0.19, 0.86)	<0.001
Abnormal LV geometry	0.14 (0.12, 0.48)	<0.001
Abnormal LV diastolic function	0.58 (0.26, 0.79)	0.006

Models are adjusted for age, field center, Hispanic/Latino background, and current hypertension (defined as BP >140/90 or antihypertensive therapy).

Supplemental Table 1. Differences in Measures of Left Ventricle Structure and Function by Type of Hypertensive Disorders

of Pregnancy.

	De Novo Hypertensive Disorders of Pregnancy History					
Echocardiographic Measures	None	Gestational Hypertension	Preeclampsia	Eclampsia	p-trend	
Continuous Measures						
LV ejection fraction, %	71.72 (4.44)	70.65 (4.65)	71.22 (4.26)	69.36 (6.23)	<0.001	
LV stroke volume, mL	59.86 (11.15)	63.64 (13.03)	61.90 (11.56)	59.34 (10.67)	<0.001	
LV mass index, g/m ²	75.61 (15.91)	80.06 (20.75)	75.70 (16.42)	76.86 (18.35)	0.19	
LV end-diastolic diameter, cm	4.23 (0.36)	4.28 (0.44)	4.26 (0.35)	4.19 (0.38)	0.60	
LVMI/EDV ratio	0.93 (0.23)	0.91 (0.27)	0.89 (0.21)	0.91 (0.20)	0.003	
LV relative wall thickness, cm	0.44 (0.07)	0.46 (0.07)	0.44 (0.07)	0.47 (0.09)	<0.001	
PTRV, cm/s	219.72 (30.37)	226.58 (29.95)	221.93 (23.70)	222.72 (27.09)	0.12	
Lateral E/e' ratio	8.73 (3.38)	9.22 (3.85)	8.41 (2.62)	8.59 (2.73)	0.01	
Categorical Measures						
Concentric LV remodeling, %	45.2	50.4	39.6	66.6	0.07	
Concentric LVH, %	8.3	16.8	9.7	4.1	0.005	
Eccentric LVH, %	2.3	5.1	0.6	4.2	0.99	
Abnormal LV geometry, %	55.9	72.2	50.2	74.9	<0.001	
Abnormal LV diastolic function, %	35.3	38.7	29.7	32.7	0.38	

Supplemental Table 2. Associations between Gestational Hypertension and Preeclampsia and Measures of Left Ventricle

Structure and Function.

	Gestational Hypertension					
	Model 1		Model 2		Model 3	
Echocardiographic Measures	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value
Continuous Measures						
LV ejection fraction, %	-0.92 (-1.60, -0.24)	0.008	-0.77 (-1.45, -0.09)	0.027	-0.61 (-1.32, 0.09)	0.09
LV stroke volume, mL	2.82 (0.95, 4.69)	0.003	1.88 (0.11, 3.65)	0.038	1.14 (-0.53, 2.81)	0.18
LV mass index, g/m ²	5.20 (2.00, 8.41)	0.002	2.63 (-0.45, 5.71)	0.09	1.76 (-1.38, 4.90)	0.27
LV end-diastolic diameter, cm	0.17 (-0.57, 0.90)	0.66	0.002 (-0.71, 0.72)	1.0	-0.27 (-0.96, 0.43)	0.45
LVMI/EDV ratio	0.009 (-0.04, 0.06)	0.69	-0.005 (-0.05, 0.04)	0.83	-0.0006 (-0.05, 0.05)	0.98
LV relative wall thickness, cm	0.27 (0.17, 0.38)	<0.001	0.18 (0.07, 0.29)	0.002	0.12 (0.01, 0.23)	0.03
PTRV, cm/s	9.07 (2.79, 15.35)	0.005	4.82 (-1.64, 11.29)	0.14	1.96 (-4.33, 8.26)	0.54
Categorical Measures						
Concentric LV remodeling, %	1.38 (0.97, 1.96)	0.07	1.32 (0.92, 1.90)	0.13	1.23 (0.85, 1.79)	0.27
Concentric LVH, %	2.48 (1.60, 3.87)	<0.001	1.76 (1.09, 2.85)	0.021	1.54 (0.92, 2.58)	0.10
Eccentric LVH, %	2.24 (1.01, 4.98)	0.048	1.80 (0.78, 4.18)	0.17	1.89 (0.74, 4.79)	0.18
Abnormal LV geometry, %	2.44 (1.69, 3.52)	<0.001	1.96 (1.34, 2.86)	<0.001	1.79 (1.19, 2.69)	0.005
Abnormal LV diastolic function, %	1.86 (1.30, 2.66)	<0.001	1.34 (0.92, 1.94)	0.12	1.17 (0.80, 1.71)	0.42
	Preeclampsia					
	Model 1		Model 2		Model 3	
Echocardiographic Measures	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value
Continuous Measures						
LV ejection fraction, %	-0.55 (-1.35, 0.24)	0.17	-0.46 (-1.25, 0.32)	0.25	-0.43 (-1.19, 0.33)	0.27
LV stroke volume, mL	1.11 (-1.01, 3.22)	0.31	0.54 (-1.50, 2.59)	0.60	0.27 (-1.81, 2.34)	0.80
LV mass index, g/m ²	1.33 (-2.18, 4.84)	0.46	-0.34 (-3.37, 2.69)	0.83	-0.22 (-3.18, 2.74)	0.88
LV end-diastolic diameter, cm	-0.03 (-0.78, 0.72)	0.94	-0.11 (-0.84, 0.63)	0.78	-0.15 (-0.82, 0.51)	0.65

LVMI/EDV ratio	-0.01 (-0.05, 0.03)	0.56	-0.02 (-0.06, 0.02)	0.27	-0.02 (-0.06, 0.02)	0.37
LV relative wall thickness, cm	0.08 (-0.06, 0.23)	0.24	0.02 (-0.11, 0.15)	0.75	0.008 (-0.12, 0.14)	0.90
PTRV, cm/s	4.40 (-2.73, 11.53)	0.23	1.41 (-5.97, 8.80)	0.71	1.19 (-6.37, 8.75)	0.76
Categorical Measures						
Concentric LV remodeling, %	0.95 (0.58, 1.57)	0.85	0.92 (0.56, 1.53)	0.75	0.86 (0.53, 1.41)	0.56
Concentric LVH, %	1.46 (0.73, 2.93)	0.28	1.14 (0.57, 2.27)	0.71	1.15 (0.57, 2.29)	0.70
Eccentric LVH, %	0.29 (0.06, 1.40)	0.12	0.26 (0.05, 1.28)	0.10	0.27 (0.06, 1.33)	0.11
Abnormal LV geometry, %	1.02 (0.62, 1.68)	0.94	0.87 (0.53, 1.43)	0.57	0.83 (0.50, 1.37)	0.46
Abnormal LV diastolic function, %	1.08 (0.56, 2.07)	0.83	0.88 (0.44, 1.79)	0.73	0.78 (0.37, 1.64)	0.51

